6541 — Tanvex Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00
- TWD10.99bn
- TWD11.69bn
- TWD61.41m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -2,274 | -2,104 | -1,543 | -1,641 | -2,137 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 109 | 80.5 | 6.35 | 120 | 367 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 50.9 | 15.6 | -93.8 | -94.2 | 10.8 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -1,899 | -1,788 | -1,387 | -1,334 | -1,434 |
Capital Expenditures | -93.6 | -67.5 | -30.3 | -96.1 | -71.3 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 1,913 | -176 | 5.66 | -1.27 | -12.2 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 1,819 | -243 | -24.7 | -97.4 | -83.6 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 914 | 1,730 | 1,597 | -123 | 1,080 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 797 | -359 | 154 | -1,437 | -405 |